The World Journal of Biological Psychiatry · 2000 · 14 citations · 32 references
MedicineImmunologyPsychiatryNeuropharmacologyNeuropsychiatryPsychopharmacologyAntipsychotic PharmacologyAntipsychotic PharmacotherapyAntipsychotic TherapyPsychiatric Effects Of MedicationsSchizophrenia PharmacotherapySchizophrenia Spectrum DisordersAntipsychotic ActionAntipsychotic EfficacyAntipsychotic Side EffectsCd8 Positive T CellsCd8 T Cell ActivationHaloperidol PharmacologyImmunomodulatory EffectsPsychoneuroimmune Mechanisms
There are some reports describing concurrent changes in lymphocytic and monocytic activities in schizophrenia. In this study we investigated T cell activity in schizophrenic patients by measuring the release of interleukin-2 (IL-2) and soluble interleukin-2 receptor (sIL-2R) by T cells and the percentages of CD4+ and CD8+ cells in blood. The release of IL-2 and sIL-2R by T cells was evaluated in dilute whole blood after in-vitro stimulation with phytohemagglutinin. IL-2 levels and the percentage of CD4-cells tended to decrease and sIL-2R levels decreased significantly in schizophrenic patients. Haloperidol and perazine significantly decreased IL-2 levels and increased sIL-2R levels and the percentage CD4-cells. IL-2 and sIL-2R levels were lower in patients with a predominance of positive symptoms. The neuroleptic-induced increase in sIL-2R levels was higher in patients with a predominance of positive symptoms compared with those in whom both positive and negative symptoms were severe. The study has shown that T-cell activity is reduced in schizophrenia and that neuroleptics may have immunomodulatory properties.
32
Cytokine-specific central monoamine alterations induced by interleukin-1, -2 and -6
Steve Zalcman, Julia M. Green-Johnson, Linda Murray et al. · Brain Research · 1994 · 438 citations